Thymic epithelial tumors (TETs) are rare neoplasms arising from the epithelial cells of the thymus with an incidence of 0.13 per 100,000 person/year in the United States[@b1]. According to the 2004 World Health Organization (WHO) classification, TETs are divided into thymomas (A, A/B, B1, B2, B3 subtypes) and thymic carcinomas (TCs) based on the tumor cell morphology, atypia, and on the extent of the thymocyte component[@b2]. The diagnosis of TETs by and large relies on histology supported by immunohistochemistry[@b3].

Although thymomas can be relatively indolent, with a 10-year survival of almost 100% for type A thymoma, TCs are much more aggressive with 5-year survival rate of only 50%[@b3]. Surgical resection is the cornerstone treatment for operable tumors. Besides histotype, prognosis is determined by the stage at the diagnosis and completeness of removal in resectable cases. The treatment of advanced TETs however is limited to chemotherapy which usually is not curative[@b3].

Targeted therapies against "actionable" genetic alterations in individual tumors have yielded impressive results in several types of cancers[@b4]. Despite a few case reports of dramatic responses to single agent-targeted therapies[@b5][@b6][@b7][@b8], the development of a rational targeted therapy for TETs has been hampered by insufficient knowledge of the genetic alterations of these tumors. Although the next generation sequencing (NGS) approach has shed light on the cancer genome of several common cancer types[@b9], efforts on mapping the genetic makeup of rare tumors such as TETs has lagged behind, and the knowledge of TETs at the genomic level is limited to the sporadic reports of *TP53* and *KIT* mutations[@b3][@b10].

Large scale efforts to catalogue genetic mutations in cancer such as the cancer genome atlas (TCGA) have employed samples obtained from resection of the primary tumors[@b11]. However, solid tumors are heterogeneous and that advanced tumors have dynamically evolved at the genetic level[@b12]. By whole genome and transcriptome sequencing, we previously demonstrated that common cancer-associated gene mutations were rare in an aggressive B3 thymoma[@b13]. Very recently, we identified a unique somatic missense mutation in the *GTF2I* gene that is prevalent in indolent early stage TETs and associated with good prognosis[@b14]. Genomic studies of advanced-stage TETs have not been performed yet.

In this study, we profiled somatic genetic variations in 78 advanced-stage TET samples with the aid of targeted-capture sequencing of a panel of 197 cancer-related genes ([Table S1](#s1){ref-type="supplementary-material"}). Advanced TCs exhibited a higher incidence of somatic non-synonymous mutations than advanced stage thymomas. Moreover, we observed recurrent somatic mutations of epigenetic regulatory genes in TCs but not in thymomas. To our knowledge, this study represents the largest series of advanced-stage TETs which have been characterized by targeted sequencing.

Results
=======

Patient characteristics
-----------------------

A total of 82 TET patients were enrolled in the molecular profiling study from March 2011 to December 2012. Out of the 82 patients, tumor specimens and paired blood samples were obtained from 78 patients, including 31 thymomas and 47 TCs ([Table 1](#t1){ref-type="table"}), and were processed for sequence analysis. According to the Masaoka staging system[@b2], 4 patients had stage III, 24 stage IVA and 50 stage IVB disease ([Table 1](#t1){ref-type="table"}). All patients were not eligible for surgery or radiation therapy.

Exome capture sequencing and somatic mutation analysis
------------------------------------------------------

We identified a total of 86 somatic variations affecting 39 genes ([Table S2](#s1){ref-type="supplementary-material"}) in 33 of the 78 (42%) TETs with significantly higher incidence in TCs (29/47; 62%) than thymomas (4/31; 13%) (p \< 0.0001; [Figure 1A](#f1){ref-type="fig"}). As the 197 cancer-gene panel was selected independently of the mutations found in our recent exome sequencing study of TETs[@b14], the results are in line with our previous data and further confirm that somatic mutations are more prevalent in TCs than thymomas[@b14]. Forty-eight variants, including 41 of the 64 recurrent variants, were randomly chosen for validation by Sanger sequencing using gene-specific primers and 46 (96%) variants were confirmed ([Table S2](#s1){ref-type="supplementary-material"}). Among the 86 variants, 62 were single nucleotide variations (49 missense mutations, 4 splice site mutations and 9 nonsense mutations) derived from 31 genes in 34 patients, and 24 were indels (17 frameshift and 7 inframe indels) from 15 genes in 17 patients ([Table S2](#s1){ref-type="supplementary-material"}). Thirty-seven (43%) of those somatic variations were previously reported in COSMIC and 12 in dbSNP137 and ESP6500 polymorphism databases ([Table S2](#s1){ref-type="supplementary-material"}). The latter were all tumor-associated SNPs. None of the 86 somatic mutations were identical. The tumor that carried the highest number of mutations was a TC with 13 mutations affecting 12 genes ([Table S2](#s1){ref-type="supplementary-material"}), which was probably due to the presence of mutations of the DNA repair genes *MLH1* and *XRCC1*[@b15][@b16].

Genes recurrently mutated in at least two cases included *ASXL1*, *BAP1*, *BRCA2*, *CDKN2A*, *CYLD*, *DCC*, *DNMT3A*, *HRAS*, *KIT*, *SDHA*, *SETD2*, *SMARCA4*, *TET2*, *TP53* and *WT1* ([Figure 1B](#f1){ref-type="fig"}). Among the 15 recurrently mutated genes in TETs, 13 occurred in TCs ([Figure 1C](#f1){ref-type="fig"}) but none in thymomas ([Table S2](#s1){ref-type="supplementary-material"}). Similarly, recurrent mutations of BAP1, CDKN2A, CYLD and TP53 were also found in TCs of our recent study[@b14]. To examine the potential impact of the mutations on gene function, we employed SIFT and Polyphen2 algorithms[@b17][@b18] and found that 51 of 58 SIFT- and Polyphen2-predictable somatic variations (88%) are likely to affect the gene functions based on at least one of the two prediction models ([Table S2](#s1){ref-type="supplementary-material"}). Consistent with previous reports[@b10][@b19], *TP53* mutations were found in 17% (13/78) of TETs, 26% (12/47) being in TCs and 3% (1/31) in thymomas (Chi square test, p = 0.0097), and *KIT* mutations in 9% (4/47) TCs and none in thymomas (p = 0.1471) ([Figure 1B and 1C](#f1){ref-type="fig"}). A KIT L576P mutation identified in a TC ([Table S2](#s1){ref-type="supplementary-material"}) was previously reported in melanomas that responded to imatinib treatment[@b20]. Another noticeable recurrently mutated gene was *CYLD* deubiquitinase, which functions as a negative regulator of NFKB pathway[@b21][@b22]. Four TCs (9%, 4/47) carried *CYLD* mutations and no *CYLD* mutation was detected in the 31 sequenced thymomas. This observation is in line with our previous work in independent samples where we found 3 of 16 (19%) TCs harboring *CYLD* mutations, and none in 38 sequenced thymomas[@b14]. Combined together, a total of 9 *CYLD* mutations (3 frameshift, 1 nonsense, 1 splice-site error and 4 missenses) were found in 11% (7 of 63) TCs and none in 69 thymomas (Fisher\'s exact test, p \< 0.001). A detailed summary of the *CYLD* mutations is illustrated in [Table S3](#s1){ref-type="supplementary-material"}.

Recurrent mutations of epigenetic regulatory genes in TCs
---------------------------------------------------------

Based on the recurrent mutation and truncation frequencies at the same amino acid positions described in cancer, \~140 driver genes were identified and classified into 12 core pathways[@b23]. Gene enrichment analysis revealed that out of the 39 mutated genes identified in this study, 27 were significantly enriched in 8 of the 12 defined core-pathways ([Figure 2A](#f2){ref-type="fig"}; [Tables S4 and S5](#s1){ref-type="supplementary-material"}), among which the chromatin modification pathway showed the highest enrichment score (Fisher\'s exact tests, p \< 0.0001, [Figure 2B](#f2){ref-type="fig"} and [Table S5](#s1){ref-type="supplementary-material"}). However, the results need to be interpreted with caution as 197 genes were pre-selected based on their association with cancers and thus the 12 core pathways may be over-represented in the panel. Intriguingly, 9 out of the 39 mutated genes identified in this study encode epigenetic regulatory proteins (chromatin remodeling, histone modification and DNA methylation) and were found mutated with significantly higher incidence in TCs (18/47, 38%) than thymomas (3/31, 10%) (p = 0.0081, Fisher\'s exact test; [Figure 2C](#f2){ref-type="fig"}), within which 7 were recurrently mutated in TCs (16/47) but not in thymomas (0/31) (Fisher\'s exact tests; p = 0.0001; [Figure 2D](#f2){ref-type="fig"}).

The mutated epigenetic regulatory genes that directly affect histone modification and chromatin remodeling include genes encoding histone deubiquitinase BAP1[@b24][@b25], polycomb chromatin binding protein ASXL1[@b26], histone H3K36 trimethyltransferase SETD2[@b27], and ATPase of the SWI-SNF complex SMARCA4[@b28] ([Figure 3A](#f3){ref-type="fig"} and [Table S2](#s1){ref-type="supplementary-material"}). Six TCs (13%) showed *BAP1* mutations ([Table S2](#s1){ref-type="supplementary-material"}) of which three were frameshift indels (A378fs, G560fs, G132fs), one nonsense (E200\*), one exon 2 splice site error and one inframe insertion (M231IWins). All are likely to be deleterious to the protein except M231IWins mutation. Similar loss-of-function mutations of *BAP1* have been documented in renal clear cell carcinoma[@b24]. Loss-of-function germline mutations of *BAP1* also predispose to uveal and cutaneous melanomas, mesothelioma, clear cell renal cancer and atpical cutaneous melanocytic proliferation[@b29]. Two *ASXL1* nonsense mutations (C594\* and Y700\*) were identified in two TCs and one missense (D756A) in a B2 thymoma ([Figure 3A](#f3){ref-type="fig"} and [Tables S2](#s1){ref-type="supplementary-material"}). A nonsense mutation of *ASXL1* has been recently reported in a cytogenetically normal B3 thymoma[@b30]. Recurrent somatic *ASXL1* mutations also occur in myelodysplastic syndrome, myeloproliferative neoplasms, and acute myeloid leukemia, and are associated with adverse outcome[@b31]. Another frequently mutated histone modification gene in TETs was the *SETD2* tumor suppressor gene, encoding the sole H3K36 trimethyltransferase in humans[@b27]. Six *SEDT2* missense mutations (G1672E, M1526I, E464Q, D1351N, K2028E and L1776R) and one frameshift deletion (H143 fs) were found in four TCs and one B2 thymoma ([Figure 3A](#f3){ref-type="fig"} and [Table S2](#s1){ref-type="supplementary-material"}). In clear cell renal carcinoma and pediatric glioma, *SETD2* loss-of-function mutations have been observed[@b32][@b33]. Whether the *SETD2* mutations, the majority of which (6/7) are missense in TETs, may disrupt its tumor suppressor function remains to be investigated.

Another group of the mutated epigenetic regulatory genes includes DNA methylation genes cytosine dioxymethyltransferase *TET2*, de-novo cytosine methyltransferase *DNMT3A*[@b34] and *WT1*, positive regulator of DNMT3A[@b35]. Four potential loss-of-function mutations of *TET2* (E452 del, L1816fs, F662fs and exon 8 splice donor site error) were found in two TCs and one AB thymoma ([Figure 3A](#f3){ref-type="fig"} and [Table S2](#s1){ref-type="supplementary-material"}). *TET2* inactivation mutations have been associated with lymphoid and myeloid malignancies[@b36]. Three TCs showed four *DNMT3A* mutations including one TC with S827fs and Y683D mutations, two other TCs with L723F and exon 23 splice acceptor site mutations respectively ([Figure 3A](#f3){ref-type="fig"} and [Table S2](#s1){ref-type="supplementary-material"}). All *DNMT3A* mutations occurred in the catalytic domain ([Figure 3A](#f3){ref-type="fig"}), which may result in impairment of enzymatic activity[@b37]. Similar *DNMT3A* mutations with high frequency spreading around the catalytic domain were also found in T-cell lymphomas, acute myeloid leukemia and recently a B2 thymoma[@b30][@b34][@b38].

Effect of mutations on overall survival and response to targeted agents
-----------------------------------------------------------------------

Although all patients with thymoma enrolled in this study had advanced-stage disease (stage IVA/IVB) ([Table 2](#t2){ref-type="table"}), the mutation frequency among thymomas was significantly lower than that observed in TCs. TET patients with somatic mutations exhibited a worse overall survival than patients without mutations (median survival 59 months vs 142 months; Log-rank Mantel-Cox, p \< 0.05, 95%CI: 1.902 to 2.912; [Figure 4A](#f4){ref-type="fig"}). Interestingly patients with tumors harboring mutant *TP53* displayed poorer overall survival than those with wild-type *TP53* (median survival 19 months vs. 106 months; Log-rank Mantel-Cox Test, p = 0.0003; 95% CI of ratio 2.234--22.39; [Figure 4B](#f4){ref-type="fig"}). However, no difference was observed in survival of TET patients with and without epigenetic regulatory gene mutations (p = 0.194).

A total of 56 patients were enrolled in phase II studies evaluating the following investigational agents ([Table 2](#t2){ref-type="table"}): (1) the multi-kinase inhibitor, sunitinib[@b5], (2) the CDK2/TRKA inhibitor, milciclib (PHA-848125AC)[@b6], (3) the histone deacetylase (HDAC) inhibitor, belinostat in combination with cisplatin, doxorubicin and cyclophosphamide (PACB)[@b39], (4) a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), cixutumumab[@b7] and (5) a trial evaluating single-agent belinostat therapy[@b8]. Six TET patients with epigenetic gene mutations received PACB treatment and all patients showed stable disease except a patient with a *SETD2* (G1672E)-mutant B2 thymoma who achieved a partial response ([Table 2](#t2){ref-type="table"}). In contrast, among 13 TET patients without epigenetic gene mutations who received PACB treatment, five showed partial response and one complete response. Nevertheless the response to PACB was not significantly different between patients with and without epigenetic gene mutations (p = 0.12). Moreover, there was no significant difference in the tumor response to the above-mentioned targeted therapies between patients with and without somatic gene mutations identified in this study ([Table 2](#t2){ref-type="table"}), although the number of patients enrolled in each of these studies is too small to draw firm conclusions[@b5][@b6][@b7][@b8][@b39].

Discussion
==========

Our report represents the largest study of somatic mutations in patients with advanced-stage TETs and aggressive histological types (i.e. 95% stage IVA/IVB and 60% TC). In addition to the previously reported *TP53* and *KIT* mutations[@b10][@b19], here we showed that chromatin remodeling, histone modification, and DNA methylation genes are frequently mutated in advanced-stage TCs. Although none of the epigenetic regulatory genes showed high mutation frequency, altogether they were present in 38% of TCs or 27% of TETs. Our finding is not without precedent. Recent NGS projects revealed high frequency of clusters of epigenetic regulatory gene mutations in kidney carcinoma, metastasizing uveal melanomas and pediatric high grade glioma, medulloblastoma, and T-lineage acute lymphoblastic leukaemia[@b26][@b32][@b33][@b34]. Considering that not all the epigenetic regulatory genes were included in our 197 cancer-associated gene panel, we might have underestimated the mutation frequencies of epigenetic regulatory genes in TCs. Whole exome sequencing of more patient samples will be required to clarify the frequency of the epigenetic regulatory gene mutations in TETs, especially in TCs.

The seven epigenetic regulatory genes (*BAP1, ASXL1, SETD2, SMARCA4, DNMT3A, TET2*, and *WT1*) have been previously categorized as drivers when mutated in other cancers[@b23] and were found recurrently mutated only in TCs but not thymomas. SIFT and Polyphen2 algorithms predicted the damaging nature of most of the mutations in these seven genes ([Table S2](#s1){ref-type="supplementary-material"}), implicating the potential importance of these mutations in TCs. The most prevalent epigenetic gene mutation was in the *BAP1* tumor suppressor gene, that has histone deubiquitinase activity[@b25]. Five (frameshift, splice-site and nonsense mutations) of the six identified mutations are likely to be deleterious to the protein[@b40]. *BAP1* mutation in clear cell renal carcinoma correlated with high tumor grade and worse prognosis[@b41]. All *BAP1* mutations affected stage IVB TCs. However, given the relatively small sample size and variability of therapies, we have not been able to establish the prognostic values of *BAP1* mutations in TCs. BAP1 interacts with ASXL1 polycomb chromatin binding protein forming a polycomb repressive deubiquitinase complex that regulates histone H2A ubiquitination[@b26]. Loss of BAP1 and ASXL1 functions are reported to compromise their tumor suppressor activities in cancer[@b26]. *ASXL1* and *BAP1* mutations were mutually exclusive and together accounted for 17% of TCs.

Mutations of de-novo cytosine methyltransferase *DNMT3A* have been reported in T-cell lymphomas which are often accompanied with mutations of *TET2* cytosine dioxymethyltransferase, an enzyme acting at an intermediate step toward methylcytosine demethylation[@b34]. Unlike T-cell lymphomas, *TET2* and *DNMT3A* mutations were mutually exclusive in TETs, indicating that the two genes may be involved in deregulation of cytosine methylation and demethylation processes independently in thymic tumors.

As the mutated epigenetic regulatory genes identified in this study function at different levels of epigenetic regulations (chromatin remodeling, histone modification and DNA methylation), it is not surprising that patients with epigenetic regulatory gene mutations may not respond to chemotherapy and HDAC inhibitor combination therapy ([Table 2](#t2){ref-type="table"}). Understanding how and whether the mutated epigenetic regulatory genes may play a role in thymic epithelial cell transformation will help to tailor specific drugs to tumors with specific epigenetic alterations, as piloted in non-small cell lung cancer and leukemia studies[@b42][@b43]. Future work requires the determination of the mutation impact on the functions of the encoded proteins and the epigenetic landscape of the tumor cells.

*TP53* mutations correlated with poorer patient survival, reflecting the high mutation frequency in stage IVB TCs. Similar findings have been published for other more common solid tumors[@b44]. However the prognostic role of mutant P53 remains controversial, probably mainly because most studies are based only on immunohistochemistry analysis[@b45].

CYLD activates NFKB signaling through deubiquitination of NFKB upstream regulators ubiquitylated by cIAP ubiquitin E3 ligase, and inhibition of cIAP by cIAP antagonist blocks NFKB activation[@b21][@b22]. Five of the 9 mutations in TETs were framshift, nonsense and splice-site error ([Figure 3B](#f3){ref-type="fig"}), which are probably non-functional, in line with the tumor suppressor role of CYLD[@b22]. Anti-inflammation drugs aspirin and prostaglandin A1 were used in a phase I trial to block NFKB signaling in cylindromatosis patients with *CYLD* mutations[@b46][@b47]. Whether similar treatment strategies may be applicable to TCs remains to be evaluated.

In conclusion, our study shows that chromatin remodeling, histone modification and DNA methylation regulatory genes are frequently mutated in TCs, and that the genetic architecture of thymoma is different from that of TCs. Further investigation on the role of epigenetic dysregulation in TC development and the potential for targeted therapy is warranted.

Methods
=======

Patients
--------

The study was approved by the institutional ethics committee at the National Cancer Institute (NCI) and performed according to institutional guidelines. All participants provided written informed consent. Patients with advanced-stage TETs who were referred to NCI and were eligible for a pilot study of molecular profiling in thoracic cancers (Clinical trial.gov ID: NCT01306045) were included. This was a large trial in which patients with advanced chest tumors (lung cancers and TETs) were molecularly profiled and treatment allocated depending on predefined molecular alterations in tumors[@b48]. Eligibility criteria included: patients with advanced disease that was not amenable to radical surgery or radiation, Eastern Cooperative Oncology Group (ECOG) performance status of 0--2 and availability of tumor tissue material (either archival tissues or new biopsies). At the same time there were several Phase II trials available at NCI for patients with advanced TETs and patients were enrolled on those studies if no predefined targetable molecular abnormality was found. Clinical data on these Phase II trials have been previously reported[@b5][@b6][@b7][@b8][@b39]. Stages were defined according to the Masaoka staging system and histotypes according to the WHO 2004 classification[@b2],

DNA extraction from formalin-fixed paraffin-embedded block sections
-------------------------------------------------------------------

Formalin-fixed paraffin-embedded (FFPE) slides prepared from fresh biopsies or archival material were stained with hematoxylin and eosin (H&E) and evaluated by a pathologist (KJK) to confirm the tumor diagnosis and select regions rich (\>80%) in tumor cells. DNA was extracted from sections of enriched epithelial tumor cells by macro-dissection from unstained FFPE blocks using DNeasy Blood & Tissue kit (Qiagen, Valencia, CA) with an extended proteinase K digestion over 24 hrs at 65°C. Control DNAs were prepared from paired patients\' peripheral blood using Agencourt Genfind v2 kit (Beckman Coulter, Brea, CA). All patients gave their written informed consent to this study that was conducted in agreement with the principles of the declaration of Helsinki and approved by the ethical institutional review board of the NIH clinical center (ClinicalTrial.gov ID\#: NCT01306045).

Massively parallel sequencing of 197 cancer-related genes
---------------------------------------------------------

A panel of 197 cancer-associated genes ([Table S1](#s1){ref-type="supplementary-material"}) were selected for targeted exome capture based on their known frequency of mutations in most common tumor types, in particular: (1) variations were reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) Cancer Gene Census or (2) were known or drivers of solid tumors not yet listed in the COSMIC census at the time this reagent was designed or (3) were in pathways under investigation within NCI for other projects. Massively parallel sequencing was performed for high depth sequencing on MiSeq sequencers (Illumina, San Diego, CA). Briefly, DNAs were extracted from clinical specimens, and were fragmented by sonication. Indexed DNA libraries were prepared by 3 consecutive steps including end-repair, A-tailing and adapter ligation to the DNA fragments. In subsequent PCR amplification steps, primers containing a flow cell attachment site (P5), sequencing primer sites for index read (Index SP) and application read 2 (Rd2 SP), unique 6 bp indices (Index) and a second flow cell attachment site (P7), were incorporated. The indexed libraries were then pooled in groups of up to 12, target enriched by Sure Select custom targeted-capture kit (Agilent) according to vendor protocol, and proceeded with paired-end (2 × 150 bp) sequencing using the Miseq V2 kit (15 M, 300 cycles). The design of the 197 genes covers about 96.3% of 9946 exons, which are equal to 682,932 bps. In the 156 sequenced samples (78 TET/blood pairs), the average sequence coverage was 125X (range 27X--420X), with 130X (27X--420X) for TETs and 121X (33X--300X) for normal blood controls.

Workflow for sequence read processing, somatic mutation call and annotation
---------------------------------------------------------------------------

Data processing and variant calling procedure mainly followed the Best Practices workflow recommended by the Broad Institute (<http://www.broadinstitute.org/gatk/guide/best-practices>). Briefly, the raw sequencing reads were mapped to human genome version 19 by Burrows-Wheeler Aligner[@b49], followed by local realignment using the GATK suite from the Broad Institute and duplicated reads were marked by Picard tools (<http://picard.sourceforge.net>). Somatic variant calling was performed on sequencing reads of matched tumor-normal samples by the Strelka somatic variant caller[@b50], and germline variant calling was done with the UnifiedGenotyper from the Broad Institute. Mutiple annotation databases and open source packages were used to annotate and predict the effects of variants, including SnpEff[@b51], dbNSFP[@b52], dbSNP 137 (NCBI), ESP6500 (NHLBI Exome Sequencing Project), and COSMIC database. SIFT scores range from 0 to 1, and scores \< 0.05 suggest that the amino acid change is damaging ([sift.jcvi.org/www/SIFT_help.html](http://sift.jcvi.org/www/SIFT_help.html)). PolyPhen-2 scores \> 0.85 are interpreted as probably damaging ([genetics.bwh.harvard.edu/pph2/dokuwiki/overview\#prediction](http://genetics.bwh.harvard.edu/pph2/dokuwiki/overview#prediction)).

The following filtering criteria were used for somatic variation calls: (1) SNVs and indels in tumors were considered somatic if they were completely absent in the paired blood samples; (2) Only SNVs and indels of \>15 reads with allelic fraction of \>15% were reported; (3) MAPQ score of \<20 were excluded for variant count; (4) Somatic SNVs and indels were reported only when they were within the open reading frames and splice sites; (5) Synonymous variations, non-coding region mutations outside splice-sites, and single nucleotide polymorphisms (SNPs) that have not been reported to be disease-related were filtered out; (6) All the identified somatic SNVs and indels were validated visually using Integrative Genomics Viewer (IGV, Broad Institute).

Validation of somatic mutations by Sanger sequencing
----------------------------------------------------

Somatic mutations identified in the study were randomly selected for validation by dideoxynucleotide Sanger sequencing on tumor/blood paired samples. Primers were designed using Primer 3.0 or Oligo 6.0 software (Molecular Biology Insights, Cascade, CO), and blast-searched against the whole human genome sequence (NCBI build 37) for primer specificity. DNAs were PCR-amplified with gene specific primers that were flanked by M13F and M13R sequences at 5′ ends for sequencing (sequences of primers are available upon request).

Statistical analysis
--------------------

Pathway enrichment analysis of mutated genes was performed using Fisher\'s exact or Chi square tests to quantify the association between the somatic mutations identified in this study and the driver gene-enriched 12 core-pathways recently described by Vogelstein et al[@b23]. Briefly the representation of each core pathway genes within the mutated genes identified in our study was compared with the representation of the core pathway genes within all the reported cancer-associated genes in the COSMIC database by Fisher\'s exact test to calculate the enrichment scores (−log \[p-value\]). We also calculated q-values from the empirical p-values by the bootstrap estimation method[@b53][@b54]. We considered q-values of ≤0.05 as an acceptable proportion of false positives in combination with p-value of ≤0.05. All the data were processed and analyzed using the statistical computing software R with specific add-on packages[@b55].

Correlations between patient and tumor characteristics and molecular results were assessed using Fisher\'s exact test. Survival curves were generated with Kaplan-Meier method, and differences evaluated using the Log-rank (Mantel-Cox) test. Overall survival was calculated from the time of initial diagnosis to death or censored to the time at which the patient was last known to be alive. All calculations were performed using PRISM version 5.0b (GraphPad Software Inc., La Jolla, CA).
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![(A). TCs exhibited higher incidence of somatic mutations than thymomas (p \< 0.0001, Chi-square test). The numbers in the bars indicate the number of cases with somatic mutations out of total number of cases analyzed. (B). Frequency of recurrent mutations in TETs. (C). Frequency of recurrent mutations in TCs.](srep07336-f1){#f1}

![Mutations of epigenetic regulatory genes in chromatin modification pathway are significantly enriched in TCs.\
(A). Bar plot shows the hierarchical order of the predefined core pathway enrichment[@b23] of the mutated genes based on their enrichment scores (−log \[p-value\]). (B). Heat map of the mutated genes within the core pathways. Yellow bars represent genes that are significantly enriched in the corresponding pathways. (C). Epigenetic gene mutations are more prevalent in TCs than in thymomas (p = 0.0053, Chi-square test). (D). Recurrent epigenetic gene mutations in TC but not in thymomas.](srep07336-f2){#f2}

![(A). Amino acid positions of recurrently mutated genes relative to the domains of the epigenetic regulatory gene-encoded proteins. ASXL1: ASXN, conserved domain at the N-terminus; ASXM, conserved domain in the middle part; NR, nuclear receptor/PHD, plant homeodomain. BAP1: UCH, Ubiquitin C-terminal hydrolase; HBM, HCF-binding motif (NHNY sequence); NLS, Nuclear localization signal. DNMT3A: PWWP, a proline-tryptophan-tryptophan-proline domain; ADD, an ATRX-DNMT3-DNMT3L-type zinc finger domain; Mtase, a methyltransferase domain. SETD2: AWS, AWS domain; SET, SET domain; PS, post-SET domain; LCR, low-charge region; WW, WW domain. SMARCA4: QLQ, Gln, Leu, Gln motifi; HSA&BRK, domain associated with helicase, SANT, transcription and chromo domain helicases; ATPase Helicase, DEAD-like helicase, helicase C terminal domain; Bromo, bromodomain. TET2: Cys-rich, CXXC Cysteine rich domain; Dioxygenase, dioxygenase domain. WT1: SD, 10-AA suppression domain; REP, repression domain; Act, activation domain; Zn, Zinc finger. (B). Somatic mutation positions relative to the domains of CYLD protein. CAP, CAP-Gly domain; TRAF2, TRAF2 binding site; CAP 469--546, NEMO binding site; USP, ubiquitin specific protease domain. CYLD somatic mutations identified in this study are marked in black, and mutations identified in our recent study[@b14] are in red. X, stop codon; del, deletion; ins, insertion; fs, frameshift.](srep07336-f3){#f3}

![(A). Overall survival of TET patients with and without somatic mutations. (B). Overall survival of TET patients with and without TP53 mutations. Survival curves were generated with Kaplan-Meier method and the differences evaluated by the Log-rank (Mantel-Cox) test. mt, mutant; wt, wild-type.](srep07336-f4){#f4}

###### Patient characteristics and mutation status

                                                                                                  Cases      w/somatic mutations   w/o somatic mutations                   p-value                   mt epi   wt epi   p-value   mt TP53   wt TP53   p-value   mt BAP1   wt BAP1   p-value
  -------------------------------------------------------------------------- ---------------- ------------- --------------------- ----------------------- ----------------------------------------- -------- -------- --------- --------- --------- --------- --------- --------- ---------
  **Total**                                                                                        78                                                                                                                                                                                  
  **Median Age (range), years**                                                                53 (20--80)                                                                                                                                                                             
  **Gender**                                                                       Male            43                22                     21                              0.108                      14       29      0.305      10        33       0.084       3        40       0.793
                                                                                  Female           35                11                     24                                                         7        28                  3        32                   3        32          
  **Race**                                                                      Caucasian          62                26                     36                0.775[\*](#t1-fn2){ref-type="fn"}        16       46      0.532      12        50       0.443       5        57       1.000
                                                                                  Asian             8                 3                      5                                                         2        6                   0         8                   1         7          
                                                                                  Black             7                 4                      3                                                         3        4                   1         6                   0         7          
                                                                                Hispanian           1                 0                      1                                                         0        1                   0         1                   0         1          
  **Stage**                                                                        III              4                 1                      3               0.031[\*\*](#t1-fn3){ref-type="fn"}       1        3       0.197       0         4       0.119       0         4       0.553
                                                                                   IV A            24                 6                     18                                                         4        20                  2        22                   0        24          
                                                                                   IV B            50                26                     24                                                         16       34                 11        39                   6        44          
  **WHO histotype**                                                                 AB              3                 1                      2             0.0001[\*\*\*](#t1-fn4){ref-type="fn"}      1        2       0.005       0         3       0.010       0         3       0.038
                                                                                    B1              2                 1                      1                                                         1        1                   0         2                   0         2          
                                                                                    B2             17                 1                     16                                                         1        16                  1        16                   0        17          
                                                                                    B3              6                 1                      5                                                         0        6                   0         6                   0         6          
                                                                                   NOS              3                 0                      3                                                         0        3                   0         3                   0         3          
                                                                                    TC             42                28                     14                                                         18       24                 11        31                   6        36          
                                                                                   TNEC             5                 1                      4                                                         0        5                   1         4                   0         5          
  **Biopsy site**                                                                Primary           34                13                     21                              0.645                      9        25      1.000       5        29       0.766       3        31       1.000
                                                                                Metastais          44                20                     24                                                         12       32                  8        36                   3        41          
  **Autoimmune/other paraneoplastic diseases**[\#](#t1-fn6){ref-type="fn"}      Autoimmne          10                 1                      9             0.005[\*\*\*\*](#t1-fn5){ref-type="fn"}     1        9       0.031       0        10       0.037       1         9       0.752
                                                                              Non-autoimmune        7                 1                      6                                                         0        7                   0         7                   0         7          
                                                                                    No             61                31                     30                                                         20       41                 13        48                   5        56          

Age was calculated from birth to date of diagnosis.

\*P-values were calculated by Chi-Square test of Caucasian + Hispanian vs Black + Asian.

\*\*P-values were calculated by Chi-Square test of III + IVA vs IVB.

\*\*\*P-values were calculated by Chi-Square test of AB + B1 + B2 + B3 + thymoma NOS vs TC + TNEC.

\*\*\*\*P-values were calculated by Chi-Square test of autoimmune + nonautoimmune diseases vs no paraneoplastic diseases.

^\#^see [Table 2](#t2){ref-type="table"} for details.

NOS: thymoma not otherwise specified; mt, wt epi: mutant, wild-type epigenetic regulatory genes.

###### Patient history

  Patient ID    Sub- type   Stage   Sex   Age   Survival (mo)     Race               Autoimmune/other disease                    Biopsy Site           BEL   PACB   PHA   IMC-A12   Sutent                                 Epig MT                                             TP53 MT                \# of Somatic MT Genes
  ------------ ----------- ------- ----- ----- --------------- ----------- -------------------------------------------- ----------------------------- ----- ------ ----- --------- -------- --------------------------------------------------------------------- ---------------------------------- ------------------------
  1010109          TC       IV a     M    60         201          Black                        none                           Pre-sternal mass                      SD                                     ASXL1 C594[\*](#t2-fn2){ref-type="fn"}                                                               2
  1010168          B1       IV a     F    41         46         Caucasian                      None                             Pleural mass                                SD                                           ASXL1 D756A                                                                            2
  1010153          TC       IV b     M    64         19         Caucasian                      None                               Left Lung                         PD                SD     ASXL1 Y700[\*](#t2-fn2){ref-type="fn"}, DNMT2A S827fs, DNMT3A Y683D   C135[\*](#t2-fn2){ref-type="fn"}             3
  1010380          TC       IV b     F    45         19         Caucasian                      None                                 Brain                                                                                BAP1 G132fs                                                                            2
  1010144          TC       IV b     M    39         51           Asian                    Sarcoidosis                        Mediastinal Mass                                                                           BAP1 A378fs                                                                            2
  1010358          TC       IV b     M    59         16         Caucasian                      None                               RLL lung                    SD                                            BAP1 E200[\*](#t2-fn2){ref-type="fn"}                                                               1
  1010089          TC       IV b     M    51         26         Caucasian                      None                       Anterior mediastinal mass           SD    SD                SD                    BAP1 Ex3 splice donor; PBRM1 L1494fs                                R248Q                           4
  1010294          TC       IV b     F    64         59         Caucasian                      None                                Thymus                                                                                BAP1 G560fs                                                                            2
  1010304          TC       Iv b     F    62         16         Caucasian                      none                               Lung, RML                   SD                                                       BAP1 M231IWins                                                                           1
  1010201          TC       IV b     M    40         31         Caucasian                      None                             Right Pleural                       SD                PR                         DNMT3A Ex23 splice acceptor                                                                    1
  1010257          TC        III     M    67         53         Caucasian                      None                                 Liver                                                                       DNMT3A L723F, SMARCA4 D1235Y                                                                    2
  1010112          TC       IV b     M    69         42         Caucasian                      None                           Mediastinal Mass                      PD                                                   MEN1 S84fs                                                                             1
  1010137          TC       IV b     M    55         81         Caucasian                      None                           Medialstinal Mass                     SD                                  SETD2 (M1526I, E464Q, D1351N), SMARCA4 T910M                            R282P                           3
  1010075          B2       IV a     F    41         15         Caucasian                      None                          Soft Tissue; Thymus              PR                                                        SETD2 G1672E                                            R267W                           10
  1010024          TC       IV b     M    69         18         Caucasian                      none                              Lymph node                         SD                                                  SETD2 H143 fs                                            P27S                           2
  1010148          TC       IV b     M    67         50         Caucasian                      None                             Thymus/Liver                                                                            SETD2 K2028E                                            C176Y                           3
  1010018          AB       IV a     M    30         43           Asian                        None                           Mediastinal Mass                SD                                                        TET2 E452 del                                                                           2
  1010217          TC       IV b     M    59         17         Caucasian                      None                           Mediastinal Mass                SD                      SD                          TET2 F662fs, SETD2 L1776R                                     M237I                           4
  1010103          TC       IV b     M    62         15         Caucasian                      None                                 Liver                                                                    TET2 L1816fs, TET2 Ex8 splice donor                                                                2
  1010336          TC       IV b     F    57         69           Black                        None                            Paraspinal mass                                        SD                                  WT1 T290M                                                                             1
  1010174          TC       IV b     F    69         44           Black                        None                                 Liver                                                                                 WT1 V300E                                Q331[\*](#t2-fn2){ref-type="fn"}             3
  1010010         TNEC      IV b     M    24         38         Caucasian                Cushings disease                      Mediatinal mass                SD                                                                                                                                                 
  1010016          TC       IV b     F    39         14         Caucasian                      None                                 Liver                                                                                                                                       M133K                           3
  1010019         TNEC      IV b     M    51         64         Caucasian                Cushings disease                        Lymph Node                         SD                                                                                                                                          1
  1010038          B2       IV b     F    43         146        Caucasian                      PRCA                                 Liver                                   SD                                                                                                                                   
  1010049          B2       IV a     M    46         63         Caucasian                      None                         Anterior Mediastinal              SD            SD        SD                                                                                                                         
  1010050          TC       IV b     F    50         96         Caucasian                      None                      Pleura and pericardial mass                SD                PR                                                                                                                         
  1010054          TC       IV a     F    42         36         Caucasian                      None                           thymic resection                      PD                                                                                                                                           
  1010056          TC       IV b     F    53         58         Caucasian                      None                      Supraclavicular lymph node           PR    SD                SD                                                                                                                        2
  1010059          AB       IV b     M    44         106        Caucasian                      None                           Left pleural mass        PD                   SD                                                                                                                                   
  1010060          NOS      IV a     F    69         71         Caucasian                      PRCA                                 Lung                                    SD                                                                                                                                   
  1010061          NOS      IV a     F    64         86           Black                        None                           Thymoma resection                             SD                                                                                                                                   
  1010073          TC       IV b     M    61         18         Caucasian                      None                           Pleural effusion                                                                                                                                                                   
  1010077          B1       IV a     M    49         31         Caucasian                      None                        Thymus mediastinal mass            PR                                                                                                                                                 
  1010085          B2       IV b     M    38         98           Asian                  Infections- PCP                           Pleura                                   SD                                                                                                                                   
  1010086          B2       IV a     F    61         52           Asian                        PRCA                                Pleura                                                                                                                                                                        
  1010097          B2       IV b     M    66         142          Black                        None                              Right lung                                 SD                                                                                                                                   
  1010098          B3       IV a     F    60         75         Caucasian                      None                           Thymoma resection                                                                                                                                                                  
  1010101          B2       IV a     M    37         47         Caucasian               Ulcerative colitis                   Right Pleural Mass               PR            SD                                                                                                                                   
  1010108          B3       IV a     F    30         28         Caucasian                      None                           Mediastinal mass                                                                                                                                                                   
  1010120          B2       IV a     F    56         146        Caucasian                      PRCA                            Retroperitoneum                              SD                                                                                                                                   
  1010134          TC       IV b     M    38         14           Asian                        None                                Thymus                           PD                                                                                                                                           
  1010138          B3       IV a     F    44         35         Caucasian                      None                              Left Pleura                        SD      SD        SD                                                                                                                         
  1010152          TC       Iv b     M    59         74         Caucasian                      None                            Ant Mediastinum                      SD                                                                                                          Y234C                           1
  1010154          TC       IV b     F    76         14         Caucasian                      None                           Mediastinal Mass                SD                                                                                                                                                 
  1010178         TNEC      IV b     M    27         10         Hispanic                       None                         Left para-mediastinum                                                                                                                                                                
  1010184          B3       IV a     M    60         136        Caucasian                      None                                Thymus              PD                   PR        SD                                                                                                                        1
  1010196          B2       IV b     M    69         140        Caucasian                      None                           Mediastinal Mass                              SD                                                                                                                                   
  1010198          TC       Iv b     M    69         84         Caucasian                      None                                Kidney                                                                                                                                       G361fs                          12
  1010200          TC       IV b     M    50         37         Caucasian                      none                                 Liver                           SD                SD                                                                                                                         
  1010204          TC       IV b     F    72         22           Black                        None                        Thymectomy, RUL (lobe)             SD                                                                                                                                                 
  1010212          AB       IV a     F    63         64           Asian                        None                       Soft Tissue, Right chest            PR                                                                                                                                                 
  1010219          NOS      IV a     F    53         218        Caucasian                      None                       Thymus, pericardium & LUL                                   PR                                                                                                                         
  1010224          TC        III     M    47         16         Caucasian                      None                                Thymus                                                                                                                                                                       1
  1010232          TC       IV b     M    73         34           Black                        None                      RLL visceral pleura implant                SD                                                                                                                                          1
  1010239          B2       IV b     F    65         96         Caucasian                      MAI                               Right lung                                                                                                                                                                      
  1010242          TC       IV a     M    35         16         Caucasian                      None                                Pleura                                                                                                                                                                        
  1010253          TC       IV a     F    80         28         Caucasian                      None                         Ant mediastinal mass                    SD                SD                                                                                                                         
  1010256          TC       IV a     M    47         40         Caucasian                      None                         Ant mediastinal mass              SD                                                                                                                                                 
  1010261         TNEC       III     M    20         53         Caucasian               Cushing\'s disease                       Thymic Mass                                                                                                                                                                     
  1010264          B2       IV b     F    31         59         Caucasian                    Uveitis                           Ant Mediastinum                                        SD                                                                                                                         
  1010268          TC       IV b     M    65         12         Caucasian                      None                                Pleura                     PR                      PD                                                                                        R282W                           1
  1010281          B2        IVa     F    58         80         Caucasian     Myasthenia Gravis; Ulcerative Colitis              Lymph Node                   NE                                                                                                                                                 
  1010286          TC       IV a     F    22         53         Caucasian                      None                           Left Axilla mass                                                                                                                                                                   
  1010292          B2       IV b     M    49         19         Caucasian                      None                                Thymus                                             SD                                                                                                                         
  1010310          TC       IV b     F    72         21         Caucasian                      None                                 Liver                                             PR                                                                                                                         
  1010318          B2       IV b     M    40         102        Caucasian                      None                               Diaphragm                                           SD                                                                                                                         
  1010323          B2       IV b     F    62         73         Caucasian   Nephrotic syndrome- minimal change disease           Thymic Mass                  CR                                                                                                                                                 
  1010327          B3       IV b     M    58         128        Caucasian                      None                           Mediastinal Mass                                        SD                                                                                                                         
  1010346          TC       IV b     F    74         25         Caucasian                      None                                Thymus                                             SD                                                                                                                         
  1010347          B3       IV b     M    33         21           Asian                        None                                Thymus                                                                                                                                                                        
  1010348          B2       IV b     F    74         44         Caucasian                      PRCA                                Thymus                                             SD                                                                                                                         
  1010363          TC       IV b     F    62         15         Caucasian                      None                            Pleural Biopsy                                                                                                                                                                   2
  1010376          TC       IV b     F    64         20           Asian                        None                       Anterior mediastinal mass                                                                                                                                                             1
  1010379          TC        III     M    40         17         Caucasian                      None                                Thymus                                                                                                                                                                        
  900006335        B2       IV b     M    67         62         Caucasian               Polycythemia vera                     Pleural effusion                              PD                                                                                                                                   
  1010290         TNEC      IV b     F    36         80         Caucasian                Cushings disease                 Breast, left lateral core                                                                                                                                                              
  1010298          TC       IV a     M    45          5         Caucasian                      None                                  RUL                      PD                      PD                                                                                        P87fs                           1

PR, partial response; CR, complete response; PD, progressive disease; SD, stable disease; NE, not evaluable; Ex, exon; del, deletion; ins, insertion;

\*, stop codon; fs, frameshift; Epig, epigenetic gene;

MT, mutation.

TNEC: Thymic neuroendocrine carcinoma; TC: thymic carcinoma; NOS: thymoma not otherwise specified.

PACB: Platinum, Adriamycin and Cyclophosphamide with Belinostat.

IMC-A12 (cixutumamab): IGF-1R antibody.

Bel, Belinostat (PXD101): HDAC inhbitor.

Sutent (Sunitinib): multi-targeted receptor tyrosine kinase inhibitor.

PHA (PHA-848125AC, milciclib): CDK2/TRKA inhibitor.

MAI: Mycobacterium Avium-Intracellulare.

PRCA: Pure red cell aplasia.

PCP: Pneumocystis Pneumonia.
